

Christine Lebrun-frenay

List of Publications by Citations

Source: <https://exaly.com/author-pdf/4173563/christine-lebrun-frenay-publications-by-citations.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

163
papers

6,702
citations

43
h-index

78
g-index

231
ext. papers

7,974
ext. citations

5.1
avg, IF

5.33
L-index

#	Paper	IF	Citations
163	Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. <i>Nature Genetics</i> , 2013 , 45, 1353-60	36.3	934
162	Natural history of multiple sclerosis with childhood onset. <i>New England Journal of Medicine</i> , 2007 , 356, 2603-13	59.2	415
161	Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR study. <i>Neurology</i> , 2018 , 90, e1858-e1869	6.5	268
160	Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis. <i>JAMA Neurology</i> , 2020 , 77, 1079-1088	17.2	235
159	MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 1719-1731	5	201
158	Radiologically isolated syndrome: 5-year risk for an initial clinical event. <i>PLoS ONE</i> , 2014 , 9, e90509	3.7	190
157	Immunosuppressive therapy is more effective than interferon in neuromyelitis optica. <i>Multiple Sclerosis Journal</i> , 2007 , 13, 256-9	5	161
156	High doses of biotin in chronic progressive multiple sclerosis: a pilot study. <i>Multiple Sclerosis and Related Disorders</i> , 2015 , 4, 159-69	4	153
155	Association between clinical conversion to multiple sclerosis in radiologically isolated syndrome and magnetic resonance imaging, cerebrospinal fluid, and visual evoked potential: follow-up of 70 patients. <i>Archives of Neurology</i> , 2009 , 66, 841-6		145
154	L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients. <i>Neurology</i> , 2013 , 81, 865-71	6.5	127
153	Idiopathic acute transverse myelitis: application of the recent diagnostic criteria. <i>Neurology</i> , 2005 , 65, 1950-3	6.5	122
152	Acute fulminant demyelinating disease: a descriptive study of 60 patients. <i>Archives of Neurology</i> , 2007 , 64, 1426-32		117
151	Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study. <i>JAMA Neurology</i> , 2014 , 71, 436-41	17.2	110
150	Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial. <i>Lancet</i> , 2015 , 386, 974-81	40	105
149	Is Devic's neuromyelitis optica a separate disease? A comparative study with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2003 , 9, 521-5	5	103
148	Interferon-beta treatment in patients with childhood-onset multiple sclerosis. <i>Journal of Pediatrics</i> , 2001 , 139, 443-6	3.6	102
147	Primary Progressive Multiple Sclerosis Evolving From Radiologically Isolated Syndrome. <i>Annals of Neurology</i> , 2016 , 79, 288-94	9.4	96

146	Unexpected multiple sclerosis: follow-up of 30 patients with magnetic resonance imaging and clinical conversion profile. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2008 , 79, 195-8	5.5	92
145	Cognitive function in radiologically isolated syndrome. <i>Multiple Sclerosis Journal</i> , 2010 , 16, 919-25	5	90
144	Successful treatment of refractory generalized myasthenia gravis with rituximab. <i>European Journal of Neurology</i> , 2009 , 16, 246-50	6	86
143	Cognitive functions in neuromyelitis optica. <i>Archives of Neurology</i> , 2008 , 65, 84-8		86
142	Nonconvulsive status epilepticus of frontal origin. <i>Neurology</i> , 1999 , 52, 1174-83	6.5	85
141	Nitroso-urea-cisplatin-based chemotherapy associated with valproate: increase of haematologic toxicity. <i>Annals of Oncology</i> , 2001 , 12, 217-9	10.3	84
140	Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study. <i>Neurology</i> , 2016 , 86, 920-30	6.5	80
139	Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2008 , 14, 399-405	5	80
138	Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas. <i>European Journal of Endocrinology</i> , 2017 , 176, 769-777	6.5	79
137	Increased risk of multiple sclerosis relapse after in vitro fertilisation. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012 , 83, 796-802	5.5	77
136	Tyrosine kinase 2 variant influences T lymphocyte polarization and multiple sclerosis susceptibility. <i>Brain</i> , 2011 , 134, 693-703	11.2	76
135	Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability. <i>Journal of Neurology</i> , 2015 , 262, 2329-35	5.5	71
134	Long-term outcome of oligodendrogliomas. <i>Neurology</i> , 2004 , 62, 1783-7	6.5	71
133	Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study. <i>Neurology</i> , 2016 , 86, 771-8	6.5	57
132	Rituximab in refractory and non-refractory myasthenia: a retrospective multicenter study. <i>Muscle and Nerve</i> , 2012 , 46, 687-91	3.4	53
131	Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas with PCV chemotherapy. <i>European Journal of Neurology</i> , 2007 , 14, 391-8	6	53
130	Risk of autoimmune diseases and human papilloma virus (HPV) vaccines: Six years of case-referent surveillance. <i>Journal of Autoimmunity</i> , 2017 , 79, 84-90	15.5	51
129	Treatment of progressive forms of multiple sclerosis by cyclophosphamide: a cohort study of 490 patients. <i>Journal of the Neurological Sciences</i> , 2004 , 218, 73-7	3.2	51

128	More severe disability of North Africans vs Europeans with multiple sclerosis in France. <i>Neurology</i> , 2007 , 68, 29-32	6.5	50
127	Monitoring CD27+ memory B-cells in neuromyelitis optica spectrum disorders patients treated with rituximab: Results from a bicentric study. <i>Journal of the Neurological Sciences</i> , 2017 , 373, 335-338	3.2	49
126	Impact of pregnancy on conversion to clinically isolated syndrome in a radiologically isolated syndrome cohort. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 1297-302	5	48
125	Acute aphasia in multiple sclerosis: A multicenter study of 22 patients. <i>Neurology</i> , 2004 , 62, 974-7	6.5	45
124	Cancer Risk in Patients with Multiple Sclerosis: Potential Impact of Disease-Modifying Drugs. <i>CNS Drugs</i> , 2018 , 32, 939-949	6.7	44
123	A benign form of neuromyelitis optica: does it exist?. <i>Archives of Neurology</i> , 2011 , 68, 918-24		44
122	Cervical spinal cord atrophy: An early marker of progressive MS onset. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018 , 5, e435	9.1	43
121	Can high central nervous system penetrating antiretroviral regimens protect against the onset of HIV-associated neurocognitive disorders?. <i>Aids</i> , 2014 , 28, 493-501	3.5	43
120	Cancer and multiple sclerosis in the era of disease-modifying treatments. <i>Journal of Neurology</i> , 2011 , 258, 1304-11	5.5	43
119	First-line nitrosourea-based chemotherapy in symptomatic non-resectable supratentorial pure low-grade astrocytomas. <i>European Journal of Neurology</i> , 2005 , 12, 685-90	6	43
118	Adult-onset genetic leukoencephalopathies: a MRI pattern-based approach in a comprehensive study of 154 patients. <i>Brain</i> , 2015 , 138, 284-92	11.2	41
117	Characteristics in limbic encephalitis with anti-adenylate kinase 5 autoantibodies. <i>Neurology</i> , 2017 , 88, 514-524	6.5	40
116	Excess Mortality in Patients with Multiple Sclerosis Starts at 20 Years from Clinical Onset: Data from a Large-Scale French Observational Study. <i>PLoS ONE</i> , 2015 , 10, e0132033	3.7	40
115	Radiologically Isolated Syndrome: 10-Year Risk Estimate of a Clinical Event. <i>Annals of Neurology</i> , 2020 , 88, 407-417	9.4	35
114	Levocarnitine administration in multiple sclerosis patients with immunosuppressive therapy-induced fatigue. <i>Multiple Sclerosis Journal</i> , 2006 , 12, 321-4	5	35
113	Tear analysis in clinically isolated syndrome as new multiple sclerosis criterion. <i>Multiple Sclerosis Journal</i> , 2010 , 16, 87-92	5	33
112	CLIPPERS and its mimics: evaluation of new criteria for the diagnosis of CLIPPERS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019 , 90, 1027-1038	5.5	32
111	Efficacy and safety profile of memantine in patients with cognitive impairment in multiple sclerosis: A randomized, placebo-controlled study. <i>Journal of the Neurological Sciences</i> , 2016 , 363, 69-76	3.2	32

110	Up-front chemotherapy with fotemustine (F) / cisplatin (CDDP) / etoposide (VP16) regimen in the treatment of 33 non-removable glioblastomas. <i>European Journal of Cancer</i> , 2000 , 36, 1026-31	7.5	32
109	Therapeutic target of memory B cells depletion helps to tailor administration frequency of rituximab in myasthenia gravis. <i>Journal of Neuroimmunology</i> , 2016 , 298, 79-81	3.5	31
108	International consensus on quality standards for brain health-focused care in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 1809-1818	5	31
107	Immunization and multiple sclerosis: Recommendations from the French multiple sclerosis society. <i>Multiple Sclerosis and Related Disorders</i> , 2019 , 31, 173-188	4	26
106	Radiologically isolated syndrome in children: Clinical and radiologic outcomes. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017 , 4, e395	9.1	24
105	Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis. <i>Neurology</i> , 2019 , 93, e635-e646	6.5	24
104	Longitudinal follow-up of vision in a neuromyelitis optica cohort. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 1320-2	5	23
103	Relevance of lipopolysaccharide levels in HIV-associated neurocognitive impairment: the Neuradapt study. <i>Journal of NeuroVirology</i> , 2013 , 19, 376-82	3.9	22
102	MD1003 (High-Dose Pharmaceutical-Grade Biotin) for the Treatment of Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Study. <i>CNS Drugs</i> , 2018 , 32, 661-672	6.7	22
101	EGFR immunolabeling pattern may discriminate low-grade gliomas from gliosis. <i>Journal of Neuro-Oncology</i> , 2011 , 102, 171-8	4.8	20
100	Only Follow-Up of Memory B Cells Helps Monitor Rituximab Administration to Patients with Neuromyelitis Optica Spectrum Disorders. <i>Neurology and Therapy</i> , 2018 , 7, 373-383	4.6	19
99	Progressive Multifocal Leukoencephalopathy Incidence and Risk Stratification Among Natalizumab Users in France. <i>JAMA Neurology</i> , 2020 , 77, 94-102	17.2	18
98	Immunoglobulin G4-related hypertrophic pachymeningitis: A case-oriented review. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019 , 6, e568	9.1	17
97	Tear analysis as a tool to detect oligoclonal bands in radiologically isolated syndrome. <i>Revue Neurologique</i> , 2015 , 171, 390-3	3	17
96	CD62L test at 2 years of natalizumab predicts progressive multifocal leukoencephalopathy. <i>Neurology</i> , 2016 , 87, 2491-2494	6.5	17
95	New insights into the burden and costs of multiple sclerosis in Europe: Results for France. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 65-77	5	17
94	A prospective study of patients with brain MRI showing incidental t2 hyperintensities addressed as multiple sclerosis: a lot of work to do before treating. <i>Neurology and Therapy</i> , 2014 , 3, 123-32	4.6	17
93	Comparison of Simoa and Ella to assess serum neurofilament-light chain in multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2021 , 8, 1141-1150	5.3	17

92	Decreased prevalence of cancer in patients with multiple sclerosis: A case-control study. <i>PLoS ONE</i> , 2017 , 12, e0188120	3.7	16
91	Inaugural tumor-like multiple sclerosis: clinical presentation and medium-term outcome in 87 patients. <i>Journal of Neurology</i> , 2018 , 265, 2251-2259	5.5	16
90	Evolution of nevi during treatment with natalizumab: A prospective follow-up of patients treated with natalizumab for multiple sclerosis. <i>Archives of Dermatology</i> , 2011 , 147, 72-6		16
89	Oligoclonal bands increase the specificity of MRI criteria to predict multiple sclerosis in children with radiologically isolated syndrome. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2019 , 5, 2055217319836664	2	15
88	The radiologically isolated syndrome. <i>Revue Neurologique</i> , 2015 , 171, 698-706	3	15
87	Double-Blind Controlled Randomized Trial of Cyclophosphamide versus Methylprednisolone in Secondary Progressive Multiple Sclerosis. <i>PLoS ONE</i> , 2017 , 12, e0168834	3.7	15
86	Evaluation of quality of life and fatigue in radiologically isolated syndrome. <i>Revue Neurologique</i> , 2016 , 172, 392-5	3	15
85	A decreasing CD4/CD8 ratio over time and lower CSF-penetrating antiretroviral regimens are associated with a higher risk of neurocognitive deterioration, independently of viral replication. <i>Journal of NeuroVirology</i> , 2017 , 23, 216-225	3.9	14
84	Cerebrospinal fluid chitinase-3-like protein 1 level is not an independent predictive factor for the risk of clinical conversion in radiologically isolated syndrome. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 669-675		14
83	Matrix metalloproteinase 9 is decreased in natalizumab-treated multiple sclerosis patients at risk for progressive multifocal leukoencephalopathy. <i>Annals of Neurology</i> , 2017 , 82, 186-195	9.4	13
82	Milder multiple sclerosis course in patients with concomitant inflammatory bowel disease. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 1135-9	5	13
81	Vaccinations in multiple sclerosis patients receiving disease-modifying drugs. <i>Current Opinion in Neurology</i> , 2021 , 34, 322-328	7.1	13
80	Imaging spectrum of Bing-Neel syndrome: how can a radiologist recognise this rare neurological complication of Waldenström's macroglobulinemia?. <i>European Radiology</i> , 2019 , 29, 102-114	8	12
79	Turcot syndrome confirmed with molecular analysis. <i>European Journal of Neurology</i> , 2007 , 14, 470-2	6	12
78	A longitudinal observational study of a cohort of patients with relapsing-remitting multiple sclerosis treated with glatiramer acetate. <i>European Journal of Neurology</i> , 2007 , 14, 1266-74	6	12
77	Progressive spastic paraparesis revealing primary hyperparathyroidism. <i>Neurology</i> , 1994 , 44, 178-9	6.5	12
76	Cutaneous Side-effects of Immunomodulators in MS. <i>International MS Journal</i> , 2011 , 17, 88-94		12
75	HMGB1/anti-HMGB1 antibodies define a molecular signature of early stages of HIV-Associated Neurocognitive Disorders (HAND). <i>Heliyon</i> , 2017 , 3, e00245	3.6	11

74	Prospective validation of the PML risk biomarker I-selectin and influence of natalizumab extended intervals. <i>Neurology</i> , 2019 , 93, 550-554	6.5	11
73	Anomalies Characteristic of Central Nervous System Demyelination: Radiologically Isolated Syndrome. <i>Neurologic Clinics</i> , 2018 , 36, 59-68	4.5	10
72	Natalizumab-PML survivors with subsequent MS treatment: Clinico-radiologic outcome. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017 , 4, e346	9.1	9
71	Immunization and multiple sclerosis: Recommendations from the French Multiple Sclerosis Society. <i>Revue Neurologique</i> , 2019 , 175, 341-357	3	9
70	Solitary sclerosis: Experience from three French tertiary care centres. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 1216	5	9
69	A Case Report of Solitary Sclerosis: This is Really Multiple Sclerosis. <i>Neurology and Therapy</i> , 2017 , 6, 259-263	4.63	9
68	Risk for nevus transformation and melanoma proliferation and invasion during natalizumab treatment: four years of dermoscopic follow-up with immunohistological studies and proliferation and invasion assays. <i>JAMA Dermatology</i> , 2014 , 150, 901-3	5.1	9
67	Treat patients with radiologically isolated syndrome when the MRI brain scan shows dissemination in time: yes. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 1531-2	5	9
66	Solitary meningeal plasmacytomas. <i>Annals of Oncology</i> , 1997 , 8, 791-5	10.3	9
65	False positivity of anti aquaporin-4 antibodies in natalizumab-treated patients. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 1231-4	5	9
64	Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 591-600	5	9
63	Should a psychotic or manic episode be considered an early manifestation of Multiple Sclerosis? A multiple case study. <i>Multiple Sclerosis and Related Disorders</i> , 2016 , 6, 93-96	4	8
62	Giant urticaria and persistent neutralizing antibodies after the first natalizumab infusion. <i>Neurology</i> , 2010 , 74, 1394-5	6.5	8
61	Pregnancy with multiple sclerosis. <i>Revue Neurologique</i> , 2021 , 177, 180-194	3	8
60	Cerebellar volume loss in radiologically isolated syndrome. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 130-133	5	8
59	Multiple immune disorders after natalizumab discontinuation: After the CIRIS, the SIRIS?. <i>Revue Neurologique</i> , 2017 , 173, 222-224	3	7
58	Endermology: a treatment for injection-induced lipoatrophy in multiple sclerosis patients treated with sub cutaneous glatiramer acetate. <i>Clinical Neurology and Neurosurgery</i> , 2011 , 113, 721-4	2	7
57	Leukoencephalopathy in multiple myeloma: two case reports. <i>Annals of Oncology</i> , 1999 , 10, 1515-7	10.3	7

56	Interleukin 17 alone is not a discriminant biomarker in early demyelinating spectrum disorders. <i>Journal of the Neurological Sciences</i> , 2016 , 368, 334-6	3.2	7
55	Five-year outcome in the copaxone observatory: a nationwide cohort of patients with multiple sclerosis starting treatment with glatiramer acetate in France. <i>Journal of Neurology</i> , 2019 , 266, 888-901	5.5	6
54	Outcome and risk of recurrence in a large cohort of idiopathic longitudinally extensive transverse myelitis without AQP4/MOG antibodies. <i>Journal of Neuroinflammation</i> , 2020 , 17, 128	10.1	5
53	Demonstration of a lexical access deficit in relapsing-remitting and secondary progressive forms of multiple sclerosis. <i>Revue Neurologique</i> , 2014 , 170, 527-30	3	5
52	Recurrent bowel occlusion with oral ondansetron with no side effects of the intravenous route: a previously unknown adverse event. <i>Annals of Oncology</i> , 1997 , 8, 919-20	10.3	5
51	Gender Inequities in the Multiple Sclerosis Community: A Call for Action. <i>Annals of Neurology</i> , 2018 , 84, 958-959	9.4	5
50	The HV3 Score: A New Simple Tool to Suspect Cognitive Impairment in Multiple Sclerosis in Clinical Practice. <i>Neurology and Therapy</i> , 2014 , 3, 113-22	4.6	4
49	Multiple sclerosis with atypical MRI presentation: Results of a nationwide multicenter study in 57 consecutive cases. <i>Multiple Sclerosis and Related Disorders</i> , 2019 , 28, 109-116	4	4
48	Association of Immunosuppression and Viral Load With Subcortical Brain Volume in an International Sample of People Living With HIV. <i>JAMA Network Open</i> , 2021 , 4, e2031190	10.4	4
47	Treatment regimens for neuromyelitis optica spectrum disorder attacks: a retrospective cohort study.. <i>Journal of Neuroinflammation</i> , 2022 , 19, 62	10.1	4
46	Cognition and quality of life in clinically isolated syndrome patients starting a disease modifying therapy in the QUALICIS study may not predict treatment response at one year. <i>Journal of the Neurological Sciences</i> , 2017 , 382, 73-78	3.2	3
45	Oral norgestrel acetate and transdermal 17-beta-estradiol for preventing post-partum relapses in multiple sclerosis: The POPARTMUS study. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 1458-1463	5	3
44	Atypical myelitis in patients with multiple sclerosis: Characterization and comparison with typical multiple sclerosis and neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 232-238	5.3	3
43	Recurrent pericarditis due to natalizumab treatment. <i>Neurology</i> , 2009 , 72, 1616-7	6.5	3
42	Impact of disease-modifying treatments in North African migrants with multiple sclerosis in France. <i>Multiple Sclerosis Journal</i> , 2008 , 14, 933-9	5	3
41	Risk Factors and Time to Clinical Symptoms of Multiple Sclerosis Among Patients With Radiologically Isolated Syndrome. <i>JAMA Network Open</i> , 2021 , 4, e2128271	10.4	3
40	Validation of a rapid and easy-to-perform screening test for neurocognitive impairment in HIV+ patients. <i>Journal of the Neurological Sciences</i> , 2020 , 410, 116664	3.2	3
39	Untreated patients with multiple sclerosis: A study of French expert centers. <i>European Journal of Neurology</i> , 2021 , 28, 2026-2036	6	3

38	Hemophagocytic Lymphohistiocytosis Gene Mutations in Adult Patients Presenting With CLIPPERS-Like Syndrome. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021 , 8,	9.1	3
37	Cerebrospinal Fluid IL-17A Could Predict Acute Disease Severity in Non-NMDA-Receptor Autoimmune Encephalitis. <i>Frontiers in Immunology</i> , 2021 , 12, 673021	8.4	3
36	Digestive side-effects with teriflunomide: Thoughts on lactose. <i>Revue Neurologique</i> , 2018 , 174, 722-725	3	3
35	The effectiveness of natalizumab vs fingolimod-A comparison of international registry studies. <i>Multiple Sclerosis and Related Disorders</i> , 2021 , 53, 103012	4	3
34	How to switch disease-modifying treatments in multiple sclerosis: Guidelines from the French Multiple Sclerosis Society (SFSEP). <i>Multiple Sclerosis and Related Disorders</i> , 2021 , 53, 103076	4	3
33	The multiple sclerosis prodrome is just unspecific symptoms in radiologically isolated syndrome patients - No. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 1824-1826	5	3
32	Video-oculography in multiple sclerosis: Links between oculomotor disorders and brain magnetic resonance imaging (MRI). <i>Multiple Sclerosis and Related Disorders</i> , 2020 , 40, 101969	4	2
31	Treating asymptomatic bacteriuria before immunosuppressive therapy during multiple sclerosis: Should we do it?. <i>Multiple Sclerosis and Related Disorders</i> , 2017 , 18, 161-163	4	2
30	Radiologically isolated syndrome should be treated with disease-modifying therapy - Commentary. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 1821-1823	5	2
29	CCR5 Blockade in Inflammatory PML and PML-IRIS Associated With Chronic Inflammatory DiseasesS Treatments. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022 , 9,	9.1	2
28	Effects on Melanoma Cell Lines Suggest No Significant Risk of Melanoma Under Cladribine Treatment. <i>Neurology and Therapy</i> , 2020 , 9, 599-604	4.6	2
27	BEST-MS: A prospective head-to-head comparative study of natalizumab and fingolimod in active relapsing MS. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 1556-1563	5	2
26	Memory B Cells Predict Relapse in Rituximab-Treated Myasthenia Gravis. <i>Neurotherapeutics</i> , 2021 , 18, 938-948	6.4	2
25	Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021 , 8,	9.1	2
24	De novo convulsive status epilepticus in patients with multiple sclerosis treated with dalfampridine. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 618-621	5	2
23	Alexithymia in multiple sclerosis: Clinical and radiological correlations. <i>Revue Neurologique</i> , 2021 , 177, 302-311	3	2
22	Determinants of therapeutic lag in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 1838-1851	5	2
21	Bevacizumab: Is the lower the better for glioblastoma patients in progression?. <i>Bulletin Du Cancer</i> , 2018 , 105, 1135-1146	2.4	2

20	Should we treat patients with radiologically isolated syndrome (RIS)? Comments. <i>Revue Neurologique</i> , 2018 , 174, 696-698	3	2
19	Impact of executive dysfunction on naming ability in multiple sclerosis. <i>Revue Neurologique</i> , 2019 , 175, 552-559	3	1
18	Moving to fingolimod from natalizumab in multiple sclerosis-reply. <i>JAMA Neurology</i> , 2014 , 71, 925	17.2	1
17	Carnitine serum levels and levocarnitine administration in multiple sclerosis patients treated with natalizumab. <i>European Journal of Neurology</i> , 2011 , 18, e63-4	6	1
16	Smaller limbic structures are associated with greater immunosuppression in over 1000 HIV-infected adults across five continents: Findings from the ENIGMA-HIV Working Group		1
15	MRI findings in blinded trials should be available to treating physicians - Yes. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 812-813	5	1
14	The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021.. <i>Multiple Sclerosis Journal</i> , 2022 , 13524585211069068	5	1
13	Kappa Free Light Chains, Soluble Interleukin-2 Receptor, and Interleukin-6 Help Explore Patients Presenting With Brain White Matter Hyperintensities.. <i>Frontiers in Immunology</i> , 2022 , 13, 864133	8.4	1
12	Long-Term Effectiveness, Safety and Tolerability of Fingolimod in Patients with Multiple Sclerosis in Real-World Treatment Settings in France: The VIRGILE Study.. <i>Neurology and Therapy</i> , 2022 , 1	4.6	0
11	Multiple sclerosis: Is there a risk of worsening after yellow fever vaccination?. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 2280-2283	5	0
10	Digital biomarkers can highlight subtle clinical differences in radiologically isolated syndrome compared to healthy controls. <i>Journal of Neurology</i> , 2021 , 268, 1316-1322	5.5	0
9	Relapses in Patients Treated with High-Dose Biotin for Progressive Multiple Sclerosis. <i>Neurotherapeutics</i> , 2021 , 18, 378-386	6.4	0
8	Comparative Effectiveness of Natalizumab Versus Anti-CD20 in Highly Active Relapsing-Remitting Multiple Sclerosis After Fingolimod Withdrawal.. <i>Neurotherapeutics</i> , 2022 , 1	6.4	0
7	Uncommon foreign body reaction caused by derivation drain mimicking high grade CNS tumor. <i>Journal of the Neurological Sciences</i> , 2014 , 340, 237-8	3.2	
6	Signes et symptômes de la sclérose en plaques 2017 , 3-78		
5	Country break-out session highlights. <i>Neurodegenerative Disease Management</i> , 2015 , 5, 31-7	2.8	
4	Les traitements de première ligne dans la sclérose en plaques. <i>Pratique Neurologique - FMC</i> , 2012 , 3, 73-89	0	
3	Les syndromes radiologiquement isolés. <i>Pratique Neurologique - FMC</i> , 2010 , 1, F25-F28	0	

2 Les syndromes radiologiquement isolés. *Neurologie Com*, **2010**, 2, 139-141

1 Diagnostic positif de la sclérose en plaques **2017**, 79-111